#glp-1 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #glp-1, aggregated by home.social.
-
The Pill That Could Reshape the Obesity Market: Inside the Aleniglipron Trial
Like and share if you enjoyed this.
-
The Pill That Could Reshape the Obesity Market: Inside the Aleniglipron Trial
Like and share if you enjoyed this.
-
An experimental GLP-1 pill helped people with obesity or overweight lose as much as 12.1% of their body weight in just 36 weeks. Unlike injectable drugs such as Wegovy and Ozempic, aleniglipron is a… #wellness #glp1 #weightloss
Posted into FLIPBOARD EXCHANGE FEED 🗞️ @flipboard-exchange-feed-Econopass
-
New Oral GLP-1 Drug Orforglipron Beats Oral Semaglutide in Head-to-Head Phase III Trial
Stay curious — follow @1ban_news.
https://1ban.news/orforglipron-oral-glp1-beats-semaglutide-achieve3/
-
🎓💊 In a shocking twist, it seems we've finally found the true secret to #career #success for women: popping GLP-1 #pills like they're candy, and ditching that overpriced diploma. Who knew weight-loss drugs could double as a resume booster? 🚀📈
https://finance.yahoo.com/healthcare/articles/harvard-study-links-glp-1-123000637.html #weightloss #women #empowerment #GLP1 #innovation #HackerNews #ngated -
🎓💊 In a shocking twist, it seems we've finally found the true secret to #career #success for women: popping GLP-1 #pills like they're candy, and ditching that overpriced diploma. Who knew weight-loss drugs could double as a resume booster? 🚀📈
https://finance.yahoo.com/healthcare/articles/harvard-study-links-glp-1-123000637.html #weightloss #women #empowerment #GLP1 #innovation #HackerNews #ngated -
Could be in for a rough couple of days, but we'll see.
The oral Wegovy didn't work well for me, so I'm switching back to my injectable GLP-1's, and today is the first dose.
I had very few side effects when I first used them, but since it's been two months, there could be some now that they're being re-introduced. It won't be anything too crazy.
I'm so glad these medicines exist. Even if I never lose another pound, it's so wonderful to have help with my appetite.
-
Could be in for a rough couple of days, but we'll see.
The oral Wegovy didn't work well for me, so I'm switching back to my injectable GLP-1's, and today is the first dose.
I had very few side effects when I first used them, but since it's been two months, there could be some now that they're being re-introduced. It won't be anything too crazy.
I'm so glad these medicines exist. Even if I never lose another pound, it's so wonderful to have help with my appetite.
-
My stomach today isn't liking me! It's very grumbly! I have to admit the feelings are mutual. I'm not a fan of it right now either.
-
My stomach today isn't liking me! It's very grumbly! I have to admit the feelings are mutual. I'm not a fan of it right now either.
-
Amazon Pharmacy delivers GLP-1 drugs to Medicare patients for $50 a month: Same-day delivery covers 3,100 US cities and towns, expanding to nearly 4,500 by the end of 2026. The federal Bridge Program setting the price expires in 2027. https://ppc.land/amazon-pharmacy-delivers-glp-1-drugs-to-medicare-patients-for-50-a-month/ #AmazonPharmacy #GLP1 #Medicare #AffordableHealthcare #SameDayDelivery
-
Amazon Pharmacy delivers GLP-1 drugs to Medicare patients for $50 a month: Same-day delivery covers 3,100 US cities and towns, expanding to nearly 4,500 by the end of 2026. The federal Bridge Program setting the price expires in 2027. https://ppc.land/amazon-pharmacy-delivers-glp-1-drugs-to-medicare-patients-for-50-a-month/ #AmazonPharmacy #GLP1 #Medicare #AffordableHealthcare #SameDayDelivery
-
There’s No Good Way to Talk About Celebrities and Eating Disorders
-
There’s No Good Way to Talk About Celebrities and Eating Disorders
-
DATE: August 5, 2026 at 08:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Semaglutide use is associated with a lower risk of adult-onset seizures
URL: https://www.psypost.org/semaglutide-use-is-associated-with-a-lower-risk-of-adult-onset-seizures/
A new study published in the journal Neurology suggests that adults with type 2 diabetes who take the medication semaglutide might have a lower risk of developing seizures later in life. The research indicates that this protective association is not entirely explained by weight loss or improved blood sugar control. The findings provide evidence that semaglutide might offer unique benefits for brain health beyond its primary metabolic uses.
Adult-onset seizures, which begin after the age of 18, often point to underlying brain damage. These neurological events tend to arise from conditions like head trauma, strokes, or neurodegenerative diseases. “Most previous neurological research on GLP-1 receptor agonists has focused on neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Adult-onset seizure is different,” said Yoonhyuk Jang, a research professor in the Department of Neurology at Seoul National University Hospital and a postdoctoral research fellow in the Department of Immunology at Harvard Medical School.
“It is often a neurological manifestation of accumulated brain insults associated with aging, including cerebrovascular disease, neurodegeneration, traumatic brain injury, and other acquired conditions,” Jang explained. As people age, the accumulation of these brain insults increases the likelihood of developing seizures, which directly impacts overall brain health and quality of life.
“We were interested in whether semaglutide might also influence this broader aspect of brain health,” Jang said. “In that sense, we viewed adult-onset seizure not only as a clinical outcome, but also as a marker of brain vulnerability in an aging society.”
Currently, doctors rely heavily on anti-seizure medications to manage symptoms after they start. Preventive treatments that can stop or slow the development of these seizures remain limited. Semaglutide is a medication originally designed to treat type 2 diabetes by enhancing insulin production and regulating blood sugar.
The medication belongs to a class of drugs called glucagon-like peptide 1 (GLP-1) receptor agonists, which mimic a natural hormone in the body to help control metabolism. Beyond managing diabetes and assisting with weight loss, emerging evidence suggests that semaglutide might protect the nervous system. “Semaglutide has demonstrated impressive benefits across a wide range of systemic diseases, including cardiovascular and kidney disease,” Jang said. “This led us to ask a broader question: could these benefits also extend to brain health?”
The researchers designed the study to look beyond isolated symptoms and focus on the connections between metabolic regulation and the nervous system. “Our study was not simply about testing whether semaglutide lowers seizure risk,” Jang explained. “More broadly, it was an attempt to explore the brain-body axis, the concept that systemic health and brain health are deeply interconnected.”
The scientists evaluated whether semaglutide use is associated with a lower incidence of newly developed seizures in adults. They compared its effects against other common diabetes medications, such as sodium-glucose cotransporter-2 inhibitors, which help the kidneys remove sugar from the body through urine. The team analyzed data from the All of Us Research Program, a large health database tracking diverse populations in the United States.
They focused on adults with type 2 diabetes who had just started a new prescription for a diabetes medication between January 2018 and October 2023. To simulate a randomized clinical trial, the authors matched patients based on 46 different baseline characteristics. These variables included age, sex, race, income, existing medical conditions, and other medications being taken.
The study constructed two primary comparison groups, tracking patients over an average of one and a half to nearly three years using medical diagnostic codes. The first group matched 2,586 patients starting semaglutide against 7,627 patients starting other general diabetes medications. The second group matched 2,814 patients starting semaglutide against 5,791 patients starting sodium-glucose cotransporter-2 inhibitors.
The primary measure was the first occurrence of an adult-onset seizure, excluding seizures caused by dangerously low blood sugar. In the comparison between semaglutide and other general diabetes medications, the researchers found that semaglutide was associated with a lower risk of developing adult-onset seizures. Over a four-year period, the cumulative incidence of seizures in the semaglutide group was 1.01 percent, compared to 2.79 percent in the other medications group. This translates to an absolute risk reduction of 1.78 percentage points.
The analysis produced a hazard ratio of 0.44 for this comparison. A hazard ratio below 1.0 suggests a lower risk, meaning patients taking semaglutide had roughly 56 percent less hazard of developing a seizure over the study period. In practical terms, treating 70 patients with semaglutide instead of other diabetes medications was associated with one fewer patient developing seizures.
Similar patterns emerged when comparing semaglutide to sodium-glucose cotransporter-2 inhibitors. The four-year cumulative incidence of seizures was 1.07 percent for semaglutide users, compared to 2.53 percent for those on the alternative medication. The hazard ratio was 0.48, and the researchers calculated that 131 patients would need to be treated with semaglutide to observe one fewer case of adult-onset seizure.
The researchers conducted specific statistical analyses to understand if this association was driven by patients losing weight or lowering their blood sugar. They measured this by tracking changes in body mass index (BMI) and hemoglobin A1c (HbA1c). They found that these metabolic improvements accounted for very little of the observed reduction in seizure risk.
“One of the most surprising findings came from our longitudinal mediation analyses,” Jang told PsyPost. “We expected that improved glycemic control or weight loss would explain at least a substantial portion of the observed association. Instead, changes in HbA1c and BMI accounted for only a very small fraction of the effect.”
Specifically, blood sugar changes explained only 2.4 to 6.5 percent of the association, and body mass index changes explained almost none of it. “This suggests that semaglutide may influence seizure risk through mechanisms beyond its metabolic benefits,” Jang continued. “Whether these mechanisms involve neuroinflammation, direct central nervous system effects, or other biological pathways remains unknown, and answering that question will require further experimental and clinical research.”
Despite these patterns, the researchers caution against applying the findings too broadly. “The most important point is that this study should not be interpreted as evidence that semaglutide should currently be prescribed to prevent seizures,” Jang said. “Our study identifies an association, not a causal treatment recommendation.”
Observational data of this nature cannot determine that a medication directly prevents a condition. “Another important point is that our study focused specifically on adult-onset seizure in people with type 2 diabetes, not on patients with established epilepsy,” Jang noted. “These are related but distinct clinical conditions, and the findings should not automatically be generalized to all neurological diseases or all patient populations.”
The researchers also urge a measured reading of the statistical results. “This was a large population-based study involving approximately 18,000 patients with type 2 diabetes,” Jang explained. “The observed association was relatively strong, with hazard ratios that were even larger than those reported in some randomized cardiovascular outcome trials of semaglutide. Whenever an observational study finds an effect of this magnitude, it is important to interpret the results cautiously.”
While the team performed multiple tests to verify the findings, unmeasured lifestyle variables or health behaviors could still influence the results. “As larger real-world datasets become available or randomized trials are conducted, the estimated effect size may become smaller,” Jang said. “Our study should therefore be viewed as evidence supporting the possibility of a protective effect rather than definitive proof of one.”
The reliance on electronic health records presents another limitation, as medical codes can sometimes capture single seizures provoked by temporary illnesses. Additionally, the average follow-up time was somewhat short, creating a situation where many patients started the drug during the COVID-19 pandemic, a period that severely disrupted regular health care patterns.
Tracking patients over a longer period would help clarify if the protective association lasts over a lifetime. “Our long-term goal is to better understand whether GLP-1 receptor agonists can modify the biological processes that increase seizure susceptibility and influence epileptogenesis—the process by which a normal brain becomes epileptic,” Jang said. “We hope our findings encourage future research into how improving systemic health may help preserve brain health throughout aging.”
The study, “Association of Semaglutide With Lower Risk of Adult-Onset Seizure in Type 2 Diabetes,” was authored by Yong Eun, Suhwan Bong, Hyun Yong Koh, Rhonda K. Trousdale, Young Min Cho, Yoonhyuk Jang, and Soon-Tae Lee.
URL: https://www.psypost.org/semaglutide-use-is-associated-with-a-lower-risk-of-adult-onset-seizures/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Semaglutide #GLP1 #DiabetesManagement #BrainHealth #AdultOnsetSeizures #NeurologyResearch #SeizurePrevention #DiabetesTreatment #AgeingBrain #SeizureRisk reduction
-
DATE: August 5, 2026 at 08:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Semaglutide use is associated with a lower risk of adult-onset seizures
URL: https://www.psypost.org/semaglutide-use-is-associated-with-a-lower-risk-of-adult-onset-seizures/
A new study published in the journal Neurology suggests that adults with type 2 diabetes who take the medication semaglutide might have a lower risk of developing seizures later in life. The research indicates that this protective association is not entirely explained by weight loss or improved blood sugar control. The findings provide evidence that semaglutide might offer unique benefits for brain health beyond its primary metabolic uses.
Adult-onset seizures, which begin after the age of 18, often point to underlying brain damage. These neurological events tend to arise from conditions like head trauma, strokes, or neurodegenerative diseases. “Most previous neurological research on GLP-1 receptor agonists has focused on neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Adult-onset seizure is different,” said Yoonhyuk Jang, a research professor in the Department of Neurology at Seoul National University Hospital and a postdoctoral research fellow in the Department of Immunology at Harvard Medical School.
“It is often a neurological manifestation of accumulated brain insults associated with aging, including cerebrovascular disease, neurodegeneration, traumatic brain injury, and other acquired conditions,” Jang explained. As people age, the accumulation of these brain insults increases the likelihood of developing seizures, which directly impacts overall brain health and quality of life.
“We were interested in whether semaglutide might also influence this broader aspect of brain health,” Jang said. “In that sense, we viewed adult-onset seizure not only as a clinical outcome, but also as a marker of brain vulnerability in an aging society.”
Currently, doctors rely heavily on anti-seizure medications to manage symptoms after they start. Preventive treatments that can stop or slow the development of these seizures remain limited. Semaglutide is a medication originally designed to treat type 2 diabetes by enhancing insulin production and regulating blood sugar.
The medication belongs to a class of drugs called glucagon-like peptide 1 (GLP-1) receptor agonists, which mimic a natural hormone in the body to help control metabolism. Beyond managing diabetes and assisting with weight loss, emerging evidence suggests that semaglutide might protect the nervous system. “Semaglutide has demonstrated impressive benefits across a wide range of systemic diseases, including cardiovascular and kidney disease,” Jang said. “This led us to ask a broader question: could these benefits also extend to brain health?”
The researchers designed the study to look beyond isolated symptoms and focus on the connections between metabolic regulation and the nervous system. “Our study was not simply about testing whether semaglutide lowers seizure risk,” Jang explained. “More broadly, it was an attempt to explore the brain-body axis, the concept that systemic health and brain health are deeply interconnected.”
The scientists evaluated whether semaglutide use is associated with a lower incidence of newly developed seizures in adults. They compared its effects against other common diabetes medications, such as sodium-glucose cotransporter-2 inhibitors, which help the kidneys remove sugar from the body through urine. The team analyzed data from the All of Us Research Program, a large health database tracking diverse populations in the United States.
They focused on adults with type 2 diabetes who had just started a new prescription for a diabetes medication between January 2018 and October 2023. To simulate a randomized clinical trial, the authors matched patients based on 46 different baseline characteristics. These variables included age, sex, race, income, existing medical conditions, and other medications being taken.
The study constructed two primary comparison groups, tracking patients over an average of one and a half to nearly three years using medical diagnostic codes. The first group matched 2,586 patients starting semaglutide against 7,627 patients starting other general diabetes medications. The second group matched 2,814 patients starting semaglutide against 5,791 patients starting sodium-glucose cotransporter-2 inhibitors.
The primary measure was the first occurrence of an adult-onset seizure, excluding seizures caused by dangerously low blood sugar. In the comparison between semaglutide and other general diabetes medications, the researchers found that semaglutide was associated with a lower risk of developing adult-onset seizures. Over a four-year period, the cumulative incidence of seizures in the semaglutide group was 1.01 percent, compared to 2.79 percent in the other medications group. This translates to an absolute risk reduction of 1.78 percentage points.
The analysis produced a hazard ratio of 0.44 for this comparison. A hazard ratio below 1.0 suggests a lower risk, meaning patients taking semaglutide had roughly 56 percent less hazard of developing a seizure over the study period. In practical terms, treating 70 patients with semaglutide instead of other diabetes medications was associated with one fewer patient developing seizures.
Similar patterns emerged when comparing semaglutide to sodium-glucose cotransporter-2 inhibitors. The four-year cumulative incidence of seizures was 1.07 percent for semaglutide users, compared to 2.53 percent for those on the alternative medication. The hazard ratio was 0.48, and the researchers calculated that 131 patients would need to be treated with semaglutide to observe one fewer case of adult-onset seizure.
The researchers conducted specific statistical analyses to understand if this association was driven by patients losing weight or lowering their blood sugar. They measured this by tracking changes in body mass index (BMI) and hemoglobin A1c (HbA1c). They found that these metabolic improvements accounted for very little of the observed reduction in seizure risk.
“One of the most surprising findings came from our longitudinal mediation analyses,” Jang told PsyPost. “We expected that improved glycemic control or weight loss would explain at least a substantial portion of the observed association. Instead, changes in HbA1c and BMI accounted for only a very small fraction of the effect.”
Specifically, blood sugar changes explained only 2.4 to 6.5 percent of the association, and body mass index changes explained almost none of it. “This suggests that semaglutide may influence seizure risk through mechanisms beyond its metabolic benefits,” Jang continued. “Whether these mechanisms involve neuroinflammation, direct central nervous system effects, or other biological pathways remains unknown, and answering that question will require further experimental and clinical research.”
Despite these patterns, the researchers caution against applying the findings too broadly. “The most important point is that this study should not be interpreted as evidence that semaglutide should currently be prescribed to prevent seizures,” Jang said. “Our study identifies an association, not a causal treatment recommendation.”
Observational data of this nature cannot determine that a medication directly prevents a condition. “Another important point is that our study focused specifically on adult-onset seizure in people with type 2 diabetes, not on patients with established epilepsy,” Jang noted. “These are related but distinct clinical conditions, and the findings should not automatically be generalized to all neurological diseases or all patient populations.”
The researchers also urge a measured reading of the statistical results. “This was a large population-based study involving approximately 18,000 patients with type 2 diabetes,” Jang explained. “The observed association was relatively strong, with hazard ratios that were even larger than those reported in some randomized cardiovascular outcome trials of semaglutide. Whenever an observational study finds an effect of this magnitude, it is important to interpret the results cautiously.”
While the team performed multiple tests to verify the findings, unmeasured lifestyle variables or health behaviors could still influence the results. “As larger real-world datasets become available or randomized trials are conducted, the estimated effect size may become smaller,” Jang said. “Our study should therefore be viewed as evidence supporting the possibility of a protective effect rather than definitive proof of one.”
The reliance on electronic health records presents another limitation, as medical codes can sometimes capture single seizures provoked by temporary illnesses. Additionally, the average follow-up time was somewhat short, creating a situation where many patients started the drug during the COVID-19 pandemic, a period that severely disrupted regular health care patterns.
Tracking patients over a longer period would help clarify if the protective association lasts over a lifetime. “Our long-term goal is to better understand whether GLP-1 receptor agonists can modify the biological processes that increase seizure susceptibility and influence epileptogenesis—the process by which a normal brain becomes epileptic,” Jang said. “We hope our findings encourage future research into how improving systemic health may help preserve brain health throughout aging.”
The study, “Association of Semaglutide With Lower Risk of Adult-Onset Seizure in Type 2 Diabetes,” was authored by Yong Eun, Suhwan Bong, Hyun Yong Koh, Rhonda K. Trousdale, Young Min Cho, Yoonhyuk Jang, and Soon-Tae Lee.
URL: https://www.psypost.org/semaglutide-use-is-associated-with-a-lower-risk-of-adult-onset-seizures/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Semaglutide #GLP1 #DiabetesManagement #BrainHealth #AdultOnsetSeizures #NeurologyResearch #SeizurePrevention #DiabetesTreatment #AgeingBrain #SeizureRisk reduction
-
DATE: August 2, 2026 at 06:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: GLP-1 drugs like Ozempic might help clear Alzheimer’s disease plaques, new review suggests
A recent review published in Molecular and Cellular Neuroscience suggests that a popular class of diabetes and weight-loss medications might help reduce the biological markers associated with Alzheimer’s disease. By analyzing dozens of laboratory and animal studies, researchers found that GLP-1 receptor agonists consistently lower the brain proteins responsible for the progression of this dementia. The findings provide evidence for a promising avenue in future prevention efforts, though data in human patients remains limited.
Alzheimer’s disease is a progressive neurological disorder and the most common cause of dementia globally. It is biologically defined by two main microscopic features in the brain: amyloid-beta plaques and neurofibrillary tangles. Amyloid-beta is a protein fragment that can clump together outside nerve cells, forming sticky plaques that trigger inflammation and disrupt brain function.
Inside the nerve cells, another protein called tau provides structural support. In Alzheimer’s disease, tau undergoes a chemical change called hyperphosphorylation, causing it to become defective and twist into tangles. These tangles block the transport of nutrients and lead to the eventual death of the brain cell. Finding ways to clear or prevent these dual protein buildups is a primary goal for medical researchers.
Medical professionals note a strong biological connection between type 2 diabetes and Alzheimer’s disease. Patients with diabetes face a much higher risk of developing dementia later in life. In the brain, insulin resistance leads to the malfunction of specific cellular pathways, causing an increase in the enzymes that create amyloid-beta and tangle-forming tau proteins. This overlap leads scientists to suspect that medications regulating blood sugar might also protect the brain.
Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs like semaglutide and liraglutide, widely used to treat diabetes and obesity. They work by mimicking a natural hormone that prompts the body to produce insulin. Because the receptors for this hormone also exist in the brain’s memory centers, the authors of the current review wanted to evaluate whether these drugs directly impact the protein buildups that characterize Alzheimer’s disease.
The research team conducted a systematic review of scientific literature published since 2015. They identified 30 preclinical studies involving animal or cell models, alongside two clinical studies involving human patients. The researchers categorized the results based on the specific drug tested, detailing the experimental methods and the subsequent changes in amyloid-beta and tau proteins.
Liraglutide was the most thoroughly evaluated medication, featured in roughly two-thirds of the preclinical studies. Researchers tested the drug in laboratory experiments using human brain cells and in animal models such as mice, rats, and non-human primates. These models were genetically or chemically altered to mimic the protein accumulations of Alzheimer’s disease.
In these studies, liraglutide consistently lowered both target proteins. Out of fifteen animal and cell studies measuring amyloid-beta, thirteen reported a reduction. All twelve studies measuring tau reported a decrease. The researchers noted that liraglutide appeared to work by suppressing an enzyme called BACE1, which is responsible for producing amyloid-beta, and by restoring insulin signaling pathways that prevent tau from tangling.
Dulaglutide was examined in only two preclinical studies. Scientists tested the drug by injecting it into mouse models of Alzheimer’s disease over several weeks. Both studies found that dulaglutide successfully lowered amyloid-beta accumulation and tau tangles. In these animal tests, the drug also tended to improve learning and memory impairment compared to untreated mice.
The review also evaluated exenatide, which was tested in eight preclinical studies involving diabetic and Alzheimer’s mouse models. The evidence for this drug was more mixed than for liraglutide. Six out of eight studies showed a decrease in amyloid-beta, while the remaining studies found no effect. All four studies that measured tau found a reduction, though one laboratory cell study noted that the drug only decreased tau tangles when insulin was also present in the cell culture.
Semaglutide, one of the most widely known drugs in this class, was featured in four animal studies. Scientists injected the medication into genetically modified mice over periods ranging from four to eight weeks. Three of these studies documented a reduction in amyloid-beta or tau. One study found no overall effect on amyloid-beta in mice, except for a localized reduction in the memory centers of female mice.
A single study examining a related drug, tirzepatide, found no reduction in plaques. That study even noted an increase in plaque area in the cerebral cortex among male mice.
Moving to human evidence, the review analyzed two small clinical trials. The first trial involved 38 patients with Alzheimer’s disease who received daily liraglutide injections or a placebo for 26 weeks. The results were not statistically significant regarding amyloid-beta reduction or cognitive improvement. The drug did, however, prevent the decline of brain glucose consumption, which is an indicator of sustained brain cell function.
The second clinical trial observed 21 patients with mild cognitive impairment who took exenatide or a placebo for 18 months. The researchers found no change in amyloid-beta or tau levels within the patients’ spinal fluid. They did notice a decrease of amyloid-beta in plasma extracellular vesicles, which are tiny fluid-filled sacs in the blood that can reflect brain changes.
Readers might assume that because these drugs clear brain plaques in mice, they will automatically reverse Alzheimer’s disease in humans. Animal models are designed to mimic specific, isolated features of the disease, such as rapid protein buildup or early genetic mutations. They do not replicate the widespread brain cell death and complex aging processes seen in actual human patients.
Scientists are still debating whether these medications actually enter the brain in large quantities. The drugs might reduce brain proteins indirectly by lowering systemic inflammation or improving overall cardiovascular health, rather than crossing the blood-brain barrier to interact directly with nerve cells. Improvements in cardiovascular health reduce the risk of micro-strokes and blood vessel damage, which are strong contributors to dementia.
The current clinical data suggests that GLP-1 drugs do not reverse cognitive decline once Alzheimer’s disease is fully established. Because structural changes in the brain begin years before memory loss becomes apparent, these medications might only be effective as preventive treatments rather than cures for late-stage dementia.
Future research will need to focus on large-scale human trials involving early-stage interventions. By tracking patients who take these medications over longer periods before severe cognitive symptoms arise, scientists can better determine if regulating metabolic health can truly prevent the onset of Alzheimer’s disease.
The study, “The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review,” was authored by Eve Corcoran, Michael Kettlety, Urwa Mogul, Jennifer Ndiforngwah Azah, and Simon C. Cork.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #GLP1 #Ozempic #AlzheimersDisease #AlzheimersResearch #Liraglutide #Semaglutide #Dulaglutide #Exenatide #MolecularNeuroscience #DementiaPrevention
-
DATE: August 2, 2026 at 06:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: GLP-1 drugs like Ozempic might help clear Alzheimer’s disease plaques, new review suggests
A recent review published in Molecular and Cellular Neuroscience suggests that a popular class of diabetes and weight-loss medications might help reduce the biological markers associated with Alzheimer’s disease. By analyzing dozens of laboratory and animal studies, researchers found that GLP-1 receptor agonists consistently lower the brain proteins responsible for the progression of this dementia. The findings provide evidence for a promising avenue in future prevention efforts, though data in human patients remains limited.
Alzheimer’s disease is a progressive neurological disorder and the most common cause of dementia globally. It is biologically defined by two main microscopic features in the brain: amyloid-beta plaques and neurofibrillary tangles. Amyloid-beta is a protein fragment that can clump together outside nerve cells, forming sticky plaques that trigger inflammation and disrupt brain function.
Inside the nerve cells, another protein called tau provides structural support. In Alzheimer’s disease, tau undergoes a chemical change called hyperphosphorylation, causing it to become defective and twist into tangles. These tangles block the transport of nutrients and lead to the eventual death of the brain cell. Finding ways to clear or prevent these dual protein buildups is a primary goal for medical researchers.
Medical professionals note a strong biological connection between type 2 diabetes and Alzheimer’s disease. Patients with diabetes face a much higher risk of developing dementia later in life. In the brain, insulin resistance leads to the malfunction of specific cellular pathways, causing an increase in the enzymes that create amyloid-beta and tangle-forming tau proteins. This overlap leads scientists to suspect that medications regulating blood sugar might also protect the brain.
Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs like semaglutide and liraglutide, widely used to treat diabetes and obesity. They work by mimicking a natural hormone that prompts the body to produce insulin. Because the receptors for this hormone also exist in the brain’s memory centers, the authors of the current review wanted to evaluate whether these drugs directly impact the protein buildups that characterize Alzheimer’s disease.
The research team conducted a systematic review of scientific literature published since 2015. They identified 30 preclinical studies involving animal or cell models, alongside two clinical studies involving human patients. The researchers categorized the results based on the specific drug tested, detailing the experimental methods and the subsequent changes in amyloid-beta and tau proteins.
Liraglutide was the most thoroughly evaluated medication, featured in roughly two-thirds of the preclinical studies. Researchers tested the drug in laboratory experiments using human brain cells and in animal models such as mice, rats, and non-human primates. These models were genetically or chemically altered to mimic the protein accumulations of Alzheimer’s disease.
In these studies, liraglutide consistently lowered both target proteins. Out of fifteen animal and cell studies measuring amyloid-beta, thirteen reported a reduction. All twelve studies measuring tau reported a decrease. The researchers noted that liraglutide appeared to work by suppressing an enzyme called BACE1, which is responsible for producing amyloid-beta, and by restoring insulin signaling pathways that prevent tau from tangling.
Dulaglutide was examined in only two preclinical studies. Scientists tested the drug by injecting it into mouse models of Alzheimer’s disease over several weeks. Both studies found that dulaglutide successfully lowered amyloid-beta accumulation and tau tangles. In these animal tests, the drug also tended to improve learning and memory impairment compared to untreated mice.
The review also evaluated exenatide, which was tested in eight preclinical studies involving diabetic and Alzheimer’s mouse models. The evidence for this drug was more mixed than for liraglutide. Six out of eight studies showed a decrease in amyloid-beta, while the remaining studies found no effect. All four studies that measured tau found a reduction, though one laboratory cell study noted that the drug only decreased tau tangles when insulin was also present in the cell culture.
Semaglutide, one of the most widely known drugs in this class, was featured in four animal studies. Scientists injected the medication into genetically modified mice over periods ranging from four to eight weeks. Three of these studies documented a reduction in amyloid-beta or tau. One study found no overall effect on amyloid-beta in mice, except for a localized reduction in the memory centers of female mice.
A single study examining a related drug, tirzepatide, found no reduction in plaques. That study even noted an increase in plaque area in the cerebral cortex among male mice.
Moving to human evidence, the review analyzed two small clinical trials. The first trial involved 38 patients with Alzheimer’s disease who received daily liraglutide injections or a placebo for 26 weeks. The results were not statistically significant regarding amyloid-beta reduction or cognitive improvement. The drug did, however, prevent the decline of brain glucose consumption, which is an indicator of sustained brain cell function.
The second clinical trial observed 21 patients with mild cognitive impairment who took exenatide or a placebo for 18 months. The researchers found no change in amyloid-beta or tau levels within the patients’ spinal fluid. They did notice a decrease of amyloid-beta in plasma extracellular vesicles, which are tiny fluid-filled sacs in the blood that can reflect brain changes.
Readers might assume that because these drugs clear brain plaques in mice, they will automatically reverse Alzheimer’s disease in humans. Animal models are designed to mimic specific, isolated features of the disease, such as rapid protein buildup or early genetic mutations. They do not replicate the widespread brain cell death and complex aging processes seen in actual human patients.
Scientists are still debating whether these medications actually enter the brain in large quantities. The drugs might reduce brain proteins indirectly by lowering systemic inflammation or improving overall cardiovascular health, rather than crossing the blood-brain barrier to interact directly with nerve cells. Improvements in cardiovascular health reduce the risk of micro-strokes and blood vessel damage, which are strong contributors to dementia.
The current clinical data suggests that GLP-1 drugs do not reverse cognitive decline once Alzheimer’s disease is fully established. Because structural changes in the brain begin years before memory loss becomes apparent, these medications might only be effective as preventive treatments rather than cures for late-stage dementia.
Future research will need to focus on large-scale human trials involving early-stage interventions. By tracking patients who take these medications over longer periods before severe cognitive symptoms arise, scientists can better determine if regulating metabolic health can truly prevent the onset of Alzheimer’s disease.
The study, “The effects of GLP-1 receptor agonists on Alzheimer’s pathophysiology: A systematic review,” was authored by Eve Corcoran, Michael Kettlety, Urwa Mogul, Jennifer Ndiforngwah Azah, and Simon C. Cork.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #GLP1 #Ozempic #AlzheimersDisease #AlzheimersResearch #Liraglutide #Semaglutide #Dulaglutide #Exenatide #MolecularNeuroscience #DementiaPrevention
-
GLP-1 users bring back in-store clothes shopping
About 11% of Americans are on GLP-1 weight-loss drugs, according to Gallup. With changed bodies, they are trying on clothes in person to figure out what styles fit their new sizes. #News #Reuters #Newsfeed #glp1 #weightlossdrugs #shopping Read the story here: 👉 Subscribe: Keep up with the latest news from around the world: Follow Reuters on Facebook: Follow Reuters on X: Follow Reuters on Instagram:
http://fllics.com/en/video/glp-1-users-bring-back-in-store-clothes-shopping/
-
GLP-1 users bring back in-store clothes shopping
About 11% of Americans are on GLP-1 weight-loss drugs, according to Gallup. With changed bodies, they are trying on clothes in person to figure out what styles fit their new sizes. #News #Reuters #Newsfeed #glp1 #weightlossdrugs #shopping Read the story here: 👉 Subscribe: Keep up with the latest news from around the world: Follow Reuters on Facebook: Follow Reuters on X: Follow Reuters on Instagram:
http://fllics.com/en/video/glp-1-users-bring-back-in-store-clothes-shopping/
-
DATE: July 31, 2026 at 01:20PM
SOURCE: SOCIALPSYCHOLOGY.ORGTITLE: A Daily GLP-1 Pill Could Curb Heavy Drinking, Study Suggests
Source: Google News - Health
A GLP-1 pill a day may help keep problem drinking at bay. Researchers have conducted a small randomized trial of oral semaglutide, the active ingredient in Ozempic and Wegovy, for people with alcohol use disorder. Compared to those taking a placebo, people on semaglutide reported fewer days of heavy drinking, among other benefits. The findings, published in the American Journal of Psychiatry, suggest that GLP-1s could have a role in treating...
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #GLP1 #semaglutide #oralmedication #alcoholusedisorder #heavydrinking #research #psychiatry #Ozempic #Wegovy #healthnews
-
DATE: July 31, 2026 at 01:20PM
SOURCE: SOCIALPSYCHOLOGY.ORGTITLE: A Daily GLP-1 Pill Could Curb Heavy Drinking, Study Suggests
Source: Google News - Health
A GLP-1 pill a day may help keep problem drinking at bay. Researchers have conducted a small randomized trial of oral semaglutide, the active ingredient in Ozempic and Wegovy, for people with alcohol use disorder. Compared to those taking a placebo, people on semaglutide reported fewer days of heavy drinking, among other benefits. The findings, published in the American Journal of Psychiatry, suggest that GLP-1s could have a role in treating...
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #GLP1 #semaglutide #oralmedication #alcoholusedisorder #heavydrinking #research #psychiatry #Ozempic #Wegovy #healthnews
-
GLP-1 medications linked to reduced progression of select cancers. This according to Cleveland Clinic oncologists. #GLP1 #CancerResearch #MedicalResearch #Oncology #Semaglutide
https://www.instagram.com/p/DbOmaiepNmH/ -
GLP-1 medications linked to reduced progression of select cancers. This according to Cleveland Clinic oncologists. #GLP1 #CancerResearch #MedicalResearch #Oncology #Semaglutide
https://www.instagram.com/p/DbOmaiepNmH/ -
Local restaurants adjust menus as GLP-1 medications change dining habits https://www.diningandcooking.com/2740907/local-restaurants-adjust-menus-as-glp-1-medications-change-dining-habits/ #Cleveland #dining #DiningOut #Glp1 #News5Cleveland #NortheastOhioNews #WeightLossDrugs
-
Local restaurants adjust menus as GLP-1 medications change dining habits https://www.diningandcooking.com/2740907/local-restaurants-adjust-menus-as-glp-1-medications-change-dining-habits/ #Cleveland #dining #DiningOut #Glp1 #News5Cleveland #NortheastOhioNews #WeightLossDrugs
-
GLP1 Cheat Sheet
An evidence-first reference to what the GLP-1 trials actually demonstrate, distilled into ten sections. For anyone trying to separate the signal from the noise
Twelve trials define what GLP-1 medications actually do. Most of what you read references none of them.
#glp1 #ozempic #wegovy #tirzepatide #semaglutide #liraglutide #retatrutide #mounjaro #zepbound
https://substance-over-noise.beehiiv.com/products/the-glp-1-evidence-cheat-sheet
-
GLP1 Cheat Sheet
An evidence-first reference to what the GLP-1 trials actually demonstrate, distilled into ten sections. For anyone trying to separate the signal from the noise
Twelve trials define what GLP-1 medications actually do. Most of what you read references none of them.
#glp1 #ozempic #wegovy #tirzepatide #semaglutide #liraglutide #retatrutide #mounjaro #zepbound
https://substance-over-noise.beehiiv.com/products/the-glp-1-evidence-cheat-sheet
-
DATE: July 22, 2026 at 01:56PM
SOURCE: SOCIALPSYCHOLOGY.ORGTITLE: GLP-1 Drugs Linked to 17% Drop in Worker Sick Leave, Study Finds
Source: Google News - Health
GLP-1 drugs could lead to cost savings for workers and their employers by reducing employee sick leave, a U.S. government study finds. Researchers found that patients who used the drugs, sold under brand names such as Ozempic and Wegovy, took 17% less long-term sick leave than people who didn't. The study, published this month by the National Bureau of Economic Research, defines long-term sick leave as illness-related absences lasting more than...
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #GLP1 #Ozempic #Wegovy #SickLeaveReduction #EmployeeHealth #WorkplaceWellness #CostSavings #HealthEconomics #LongTermSickLeave #NBERstudy
-
DATE: July 22, 2026 at 01:56PM
SOURCE: SOCIALPSYCHOLOGY.ORGTITLE: GLP-1 Drugs Linked to 17% Drop in Worker Sick Leave, Study Finds
Source: Google News - Health
GLP-1 drugs could lead to cost savings for workers and their employers by reducing employee sick leave, a U.S. government study finds. Researchers found that patients who used the drugs, sold under brand names such as Ozempic and Wegovy, took 17% less long-term sick leave than people who didn't. The study, published this month by the National Bureau of Economic Research, defines long-term sick leave as illness-related absences lasting more than...
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #GLP1 #Ozempic #Wegovy #SickLeaveReduction #EmployeeHealth #WorkplaceWellness #CostSavings #HealthEconomics #LongTermSickLeave #NBERstudy
-
The Great Peptide Cash Grab Has Begun
-
The Great Peptide Cash Grab Has Begun
-
Weight Loss Drug Update
Semaglutide - GLP1 = 15% weight loss
Tirzepatide - GLP1 + GIP = 21-25% WL
Retatrutide - GLP1 + GIP + Glucagon = 28% WLOrforglipron (oral!) - non-peptide GLP1 = 12% WL
CagriSema - amylin combo = 23% WLSurvodutide treats fatty liver (62% improved MASH)
#Glucagon drugs (like Ret) burns energy and treats fatty liver.
Bottom line: choose the right drug based on your goals.
#Semaglutide #Tirzepatide #Retatrutide #obesity #weightloss #glp1 #gip
-
Weight Loss Drug Update
Semaglutide - GLP1 = 15% weight loss
Tirzepatide - GLP1 + GIP = 21-25% WL
Retatrutide - GLP1 + GIP + Glucagon = 28% WLOrforglipron (oral!) - non-peptide GLP1 = 12% WL
CagriSema - amylin combo = 23% WLSurvodutide treats fatty liver (62% improved MASH)
#Glucagon drugs (like Ret) burns energy and treats fatty liver.
Bottom line: choose the right drug based on your goals.
#Semaglutide #Tirzepatide #Retatrutide #obesity #weightloss #glp1 #gip
-
Weight Loss Drug Update
Semaglutide - GLP1 = 15% weight loss
Tirzepatide - GLP1 + GIP = 21-25% WL
Retatrutide - GLP1 + GIP + Glucagon = 28% WLOrforglipron (oral!) - non-peptide GLP1 = 12% WL
CagriSema - amylin combo = 23% WLSurvodutide treats fatty liver (62% improved MASH)
#Glucagon drugs (like Ret) burns energy and treats fatty liver.
Bottom line: choose the right drug based on your goals.
#Semaglutide #Tirzepatide #Retatrutide #obesity #weightloss #glp1 #gip
-
Weight Loss Drug Update
Semaglutide - GLP1 = 15% weight loss
Tirzepatide - GLP1 + GIP = 21-25% WL
Retatrutide - GLP1 + GIP + Glucagon = 28% WLOrforglipron (oral!) - non-peptide GLP1 = 12% WL
CagriSema - amylin combo = 23% WLSurvodutide treats fatty liver (62% improved MASH)
#Glucagon drugs (like Ret) burns energy and treats fatty liver.
Bottom line: choose the right drug based on your goals.
#Semaglutide #Tirzepatide #Retatrutide #obesity #weightloss #glp1 #gip
-
The ‘longevity diet’ that increases natural GLP-1, reduces body fat https://www.diningandcooking.com/2726951/the-longevity-diet-that-increases-natural-glp-1-reduces-body-fat/ #aging #Food&Drink #Glp1 #health #longevity #Mediterranean #MediterraneanDiet #nutrition #protein #StudySays #wellness
-
The ‘longevity diet’ that increases natural GLP-1, reduces body fat https://www.diningandcooking.com/2726951/the-longevity-diet-that-increases-natural-glp-1-reduces-body-fat/ #aging #Food&Drink #Glp1 #health #longevity #Mediterranean #MediterraneanDiet #nutrition #protein #StudySays #wellness
-
Cadaver Fat Injectable Gains Attention as GLP-1 Weight Loss Drives Demand for Body Contouring
📰 Original title: GLP-1s are shrinking bodies. Cadaver fat is plugging the gap
🤖 IA: It's clickbait ⚠️
👥 Users: It's clickbait ⚠️ -
CW: Glp1 (like ozempic) for medical reasons, weight, doctors being shit
This video is on GLP-1 for histamine intolerance/MCAS; there was a case of a 100 lbs woman that gained weight, presumably since she was able to eat more:
-
CW: Glp1 (like ozempic) for medical reasons, weight, doctors being shit
This video is on GLP-1 for histamine intolerance/MCAS; there was a case of a 100 lbs woman that gained weight, presumably since she was able to eat more:
-
CW: Glp1 (like ozempic) for medical reasons, weight, doctors being shit
He was incredibly blunt about me not being able to exercise. Please don't rub it in, that's ridiculous, I miss sports every day.
I said I don't care about weight loss or weight gain, my quality of life is so bad, that's the only thing I care about.
I do care about muscle loss. I'm already weak af, losing muscles seems like a really bad idea.
-
CW: Glp1 (like ozempic) for medical reasons, weight, doctors being shit
He wasn't informed about glp1 for LongCovid, he literally looked it up while I was there. So called "specialist" 🙄
Then he asked about weight loss effects, I reply I don't know, that it's 1/4 of the regular dose.
Him: if you lose weight it will be fat tissue and muscle tissue. Then, if you stop taking it, you'll gain that weight again, but it will be fat tissue only. Unless you exercise, which you can't.
-
CW: medical, glp1 (~ozempic) for medical reasons, LongCovid
She also said that taking LDN and glp1 at the same time isn't really an option. Eh. So now I don't know what to do. I guess I'll see what my friday appointment says.
-
New Oral GLP-1 Drug Orforglipron Beats Oral Semaglutide in Head-to-Head Phase III Trial
https://1ban.news/orforglipron-oral-glp1-beats-semaglutide-achieve3/
#1ban #orforglipron #oral #glp1 #beats #science -
#Semaglutid und andere #GLP1-Hemmer werden bei #Diabetes und als #Abnehmmittel eingesetzt.
Neue Studien zeigen, dass neben bekannten Risiken auch ein Risiko für #Augenschäden besteht.
https://gutepillen-schlechtepillen.de/abnehmmittel-semaglutid-augenschaeden-bestaetigt/